Login to Your Account

NewCo News

GSK Spinout NeRRe Begins with $19M, Neurokinin Drugs

By Nuala Moran
Staff Writer

Wednesday, December 26, 2012
A third spinout has emerged from GlaxoSmithKline plc's neurosciences research portfolio, with the formation of NeRRe Therapeutics Ltd. The new company begins life with a portfolio of four neurokinin-1 receptor antagonists – of which two are ready for Phase II – and £11.5 million (US$18.7 million) in venture capital funding.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription